GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » ROE %

Strongbridge Biopharma (Strongbridge Biopharma) ROE % : -105.68% (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Strongbridge Biopharma's annualized net income for the quarter that ended in Jun. 2021 was $-52.96 Mil. Strongbridge Biopharma's average Total Stockholders Equity over the quarter that ended in Jun. 2021 was $50.12 Mil. Therefore, Strongbridge Biopharma's annualized ROE % for the quarter that ended in Jun. 2021 was -105.68%.

The historical rank and industry rank for Strongbridge Biopharma's ROE % or its related term are showing as below:

SBBP' s ROE % Range Over the Past 10 Years
Min: -412.23   Med: -57.6   Max: 63.05
Current: -69.65

During the past 8 years, Strongbridge Biopharma's highest ROE % was 63.05%. The lowest was -412.23%. And the median was -57.60%.

SBBP's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.1 vs SBBP: -69.65

Strongbridge Biopharma ROE % Historical Data

The historical data trend for Strongbridge Biopharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma ROE % Chart

Strongbridge Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Get a 7-Day Free Trial -61.78 -412.23 63.05 -53.42 -65.42

Strongbridge Biopharma Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -126.71 -20.64 -68.18 -77.82 -105.68

Competitive Comparison of Strongbridge Biopharma's ROE %

For the Biotechnology subindustry, Strongbridge Biopharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strongbridge Biopharma's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's ROE % distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's ROE % falls into.



Strongbridge Biopharma ROE % Calculation

Strongbridge Biopharma's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-45.075/( (72.191+65.605)/ 2 )
=-45.075/68.898
=-65.42 %

Strongbridge Biopharma's annualized ROE % for the quarter that ended in Jun. 2021 is calculated as

ROE %=Net Income (Q: Jun. 2021 )/( (Total Stockholders Equity (Q: Mar. 2021 )+Total Stockholders Equity (Q: Jun. 2021 ))/ count )
=-52.964/( (55.847+44.391)/ 2 )
=-52.964/50.119
=-105.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2021) net income data. ROE % is displayed in the 30-year financial page.


Strongbridge Biopharma  (NAS:SBBP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-52.964/50.119
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-52.964 / 40.168)*(40.168 / 102.435)*(102.435 / 50.119)
=Net Margin %*Asset Turnover*Equity Multiplier
=-131.86 %*0.3921*2.0438
=ROA %*Equity Multiplier
=-51.7 %*2.0438
=-105.68 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-52.964/50.119
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-52.964 / -52.96) * (-52.96 / -52.26) * (-52.26 / 40.168) * (40.168 / 102.435) * (102.435 / 50.119)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0001 * 1.0134 * -130.1 % * 0.3921 * 2.0438
=-105.68 %

Note: The net income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Strongbridge Biopharma ROE % Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Executives
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c. 10 percent owner C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner 10 percent owner C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp 10 percent owner 731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson director, officer: Chief Executive Officer DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen director 60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger director 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long officer: Chief Legal Officer C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen officer: Chief Medical Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit officer: Chief Commercial Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz officer: Chief Financial Officer 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender officer: Chief Operating Officer C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Strongbridge Biopharma (Strongbridge Biopharma) Headlines

From GuruFocus